LIMINATUS PHARMA, INC. Increase (Decrease) in Prepaid Expense and Other Assets
LIMINATUS PHARMA, INC. (LIMN) reported Increase (Decrease) in Prepaid Expense and Other Assets of $212.45 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-14
- LIMINATUS PHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$495.50K.
- LIMINATUS PHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $707.95K, a 1292.35% increase year-over-year.
- LIMINATUS PHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$315.95K, a 664.33% decline year-over-year.
- LIMINATUS PHARMA, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $34.78K, a 0.87% increase year-over-year.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$495.50K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | $212.45K 10-Q · filed 2026-08-14 | -$103.50K derived: sum of 3 quarters · filed 2026-08-14 | -$68.72K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $707.95K S-1 · filed 2026-06-24 | $392.00K derived: sum of 2 quarters · filed 2026-06-24 | $426.79K derived: sum of 3 quarters · filed 2026-06-24 | $332.50K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$315.95K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | -$281.17K derived: sum of 2 quarters · filed 2026-06-24 | -$375.45K derived: sum of 3 quarters · filed 2026-08-14 | -$324.61K S-1 · filed 2026-06-24 |
| 2025-09-30 | $34.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$59.51K derived: sum of 2 quarters · filed 2026-08-14 | -$8.66K 10-Q · filed 2025-11-14 | $47.33K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$94.29K derived: 10-Q 6 month − S-1 3 month · filed 2026-08-14 | -$43.44K 10-Q · filed 2026-08-14 | $12.54K derived: sum of 3 quarters · filed 2026-08-14 | $47.03K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $50.85K S-1 · filed 2026-06-24 | $106.83K derived: sum of 2 quarters · filed 2026-06-24 | $141.31K derived: sum of 3 quarters · filed 2026-06-24 | |
| 2024-12-31 | $55.99K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $90.47K derived: sum of 2 quarters · filed 2026-06-24 | $133.25K S-1 · filed 2026-06-24 | |
| 2024-09-30 | $34.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $77.26K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | $42.78K 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |